Lawrence Eichenfield - 23 Feb 2022 Form 4 Insider Report for Forte Biosciences, Inc. (FBRX)

Role
Director
Signature
/s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact
Issuer symbol
FBRX
Transactions as of
23 Feb 2022
Net transactions value
$0
Form type
4
Filing time
24 Feb 2022, 16:02:42 UTC
Previous filing
17 Jun 2021
Next filing
02 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FBRX Stock Option (right to buy) Award $0 +25,000 $0.000000 25,000 23 Feb 2022 Common Stock 25,000 $1.27 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the one (1) year anniversary of the Date of Grant. "Date of Grant" shall mean February 23, 2022.